Filtered By:
Condition: Peripheral Vascular Disease (PVD)

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 2060 results found since Jan 2013.

High salt levels in soluble drugs may raise heart risk
Conclusion This large case control study suggested that people who had experienced disease of the heart and blood vessels were more likely to have taken sodium-containing medicines than people without cardiovascular disease. Put in other words this can be interpreted that people who took sodium-containing medicines were at a higher risk of experiencing cardiovascular disease than people who took the same medications in formulations free of sodium. The increased risk appeared to be driven mostly by an increased risk of hypertension and to a lesser extent, non-fatal stroke. The study has some strengths including its large s...
Source: NHS News Feed - November 27, 2013 Category: Consumer Health News Tags: Heart/lungs Medication Medical practice Source Type: news

There is No Benefit to Universal Carotid Artery Duplex Screening before a Major Cardiac Surgical Procedure
Conclusions: The majority of postoperative strokes after cardiac surgery are not related to extracranial carotid artery disease and they are not predicted by preoperative carotid artery duplex scan screening. Consequently, universal carotid artery duplex scan screening cannot be recommended and a selective approach should be adopted.
Source: Annals of Vascular Surgery - November 11, 2013 Category: Surgery Authors: Brian C. Adams, Ross M. Clark, Christina Paap, James M. Goff Tags: Papers Presented to the Peripheral Vascular Surgery Society - 23rd Annual Winter Meeting Source Type: research

Moderate drinking may reduce heart disease risk
Conclusion This study paints a more complicated picture than the "Pint a day keeps the doctor away" story proffered by The Sun. It seems to confirm the findings of other studies, which have shown that non-drinkers tend to have a higher risk of cardiovascular diseases than people who drink moderately. It suggests that some cardiovascular diseases (mainly those directly affecting the heart) seem to have a stronger link to a possible protective effect from alcohol than other vascular diseases, such as mini-strokes and bleeding in the brain. However, this can't be concluded with certainty due to the study design. We ...
Source: NHS News Feed - March 23, 2017 Category: Consumer Health News Tags: Heart/lungs Food/diet Lifestyle/exercise Source Type: news

Homocysteine-lowering interventions for preventing cardiovascular events.
CONCLUSIONS: In this third update of the Cochrane review, there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo on myocardial infarction, death from any cause or adverse events. In terms of stroke, this review found a small difference in effect favouring to homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo.There were uncertain effects of enalapril plus folic acid compared with enalapril on stroke; approxima...
Source: Cochrane Database of Systematic Reviews - August 17, 2017 Category: General Medicine Authors: Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M Tags: Cochrane Database Syst Rev Source Type: research

Impact of diabetes mellitus on early outcome of carotid endarterectomy.
CONCLUSIONS: In our study, perioperative neurological complications and mortality were statistically higher in diabetic patients compared to non-diabetic patients during CEA. Further research will have to show whether other treatment modalities of carotid artery stenosis and better glycaemia and dyslipidaemia controlling in diabetics can reduce this risk. PMID: 30192204 [PubMed - as supplied by publisher]
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - September 7, 2018 Category: Surgery Authors: Dimic A, Markovic M, Vasic D, Dragas M, Zlatanovic P, Mitrovic A, Davidovic L Tags: Vasa Source Type: research

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical significance of skin autofluorescence for diabetic macroangiopathy and comparison with conventional markers of atherosclerosis: a cross-sectional and prospective study
ConclusionAmong diabetic macroangiopathies, SAF is a good stroke biomarker, but not for CAD and PAD.
Source: Diabetology International - November 28, 2022 Category: Endocrinology Source Type: research

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
Conclusion Patients with PAD in ROCKET AF did not have a statistically significant higher risk of stroke or systemic embolism than patients without PAD, and there were similar efficacy outcomes in patients treated with rivaroxaban and warfarin. In PAD patients, there was a higher risk of major bleeding or NMCR bleeding with rivaroxaban when compared with warfarin (interaction P = 0.037). Further investigation is warranted to validate this subgroup analysis and determine the optimal treatment in this high-risk cohort of AF patients with PAD.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Jones, W. S., Hellkamp, A. S., Halperin, J., Piccini, J. P., Breithardt, G., Singer, D. E., Fox, K. A. A., Hankey, G. J., Mahaffey, K. W., Califf, R. M., Patel, M. R. Tags: Atrial fibrillation Source Type: research

Impact of CHA2DS2VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multipayer Analysis.
Abstract PURPOSE: The purpose of this study is to report on the effect of using CHA2DS2VASc (congestive heart failure, hypertension, age ≥75 years [doubled], type 1 or type 2 diabetes mellitus, stroke or transient ischemic attack or thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75 years, sex category [female]) rather than CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke) to determine candidacy for anticoagulant prophylaxis in insured patients with atrial fibrillation (AF). MET...
Source: Clinical Therapeutics - September 22, 2016 Category: Drugs & Pharmacology Authors: Patel AA, Nelson WW, Schein J Tags: Clin Ther Source Type: research

Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease
CONCLUSION: Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up.PMID:36216573 | DOI:10.5551/jat.63404
Source: Journal of Atherosclerosis and Thrombosis - October 10, 2022 Category: Cardiology Authors: Chung-Kuan Wu Chia-Hsun Lin Noi Yar Zih-Kai Kao Ya-Bei Yang Yun-Yi Chen Source Type: research